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Abstract
Effective antiretroviral (ARV)-based HIV prevention strategies require optimizing drug exposure 
in mucosal tissues; yet factors influencing mucosal tissue disposition remain unknown. We 
hypothesized drug transporter expression in vaginal, cervical, and colorectal tissues is a 
contributing factor and selected three efflux (ABCB1/MDR1, ABCC2/MRP2, ABCC4/MRP4) and 
three uptake (SLC22A6/OAT1, SLC22A8/OAT3, SLCO1B1/OATP1B1) transporters to further 
investigate based on their affinity for 2 ARVs central to prevention (tenofovir, maraviroc). Tissue 
was collected from 98 donors. mRNA and protein expression were quantified using qPCR and 
immunohistochemistry (IHC). 100% of tissues expressed efflux transporter mRNA. IHC localized 
them to the epithelium and/or submucosa. Multivariable analysis adjusted for age, smoking, and 
co-medications revealed significant (p<0.05) differences in efflux transporter mRNA between 
tissue types (vaginal ABCB1 3.9 fold > colorectal; vaginal ABCC2 2.9 fold>colorectal; colorectal 
ABCC4 2.0 fold>cervical). In contrast, uptake transporter mRNA was expressed in <25% of 
tissues. OAT1 protein was detected in 0% of female genital tissues and in 100% of colorectal 
tissues, but only in rare epithelial cells. These data support clinical findings of higher maraviroc 
and tenofovir concentrations in rectal tissue compared to vaginal or cervical tissue after oral 
dosing. Quantifying mucosal transporter expression and localization can facilitate antiretroviral 
selection to target these tissues.
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Introduction
Even in the era of highly active antiretroviral therapy, the HIV epidemic remains a 
significant global burden.1 Current treatment strategies alone will not curb the epidemic 
andadditional options are needed to supplement the current prevention strategies of 
condoms, circumcision, and safe sex counseling. Antiretrovirals administered topically or 
orally as pre-exposure prophylaxis (PrEP) are being investigated for their ability to protect 
individuals at high risk of acquiring HIV.2 To date, the results of these trials have been 
mixed, and demonstrate that mucosal antiretroviral pharmacology, in addition to medication 
adherence are important predictors of PrEP success.3
The sites of sexual transmission of HIV are the mucosal surfaces of the female genital tract 
and the colorectum. Yet penetration of antiretrovirals (ARVs) into female genital and 
colorectal tissue has been demonstrated to be variable and difficult to predict.4-8 For 
example, following a single dose, maraviroc concentrates two-fold in female genital tract 
tissue compared to blood plasma7 but nine-fold in colorectal tissue.6 Tenofovir achieves 
equivalent concentrations in female genital tract tissue compared to blood plasma, but 
accumulates 100-fold higher in colorectal tissue.4,8 Physiochemical properties such as 
protein binding, molecular weight, and lipophilicity alone do not account for this 
variability. 5 Understanding and predicting which ARVs have favorable characteristics for 
high mucosal tissue penetration is necessary for streamlined development of the next 
generation of prevention compounds.
Membrane drug transporters significantly impact intestinal absorption, uptake into 
hepatocytes, efflux into biliary canaliculi, penetration through the blood-brain barrier, and 
intracellular drug accumulation.9,10 Nearly all antiretrovirals have been documented to be 
substrates for, or affect the activity of, efflux and/or uptake transporters.11 Drug transporters 
are expressed on other epithelial tissues in the body such as the upper gastrointestinal tract, 
hepatocytes, the blood-brain barrier, endothelial cells, lung, and blood-testes barrier.10-12 In 
many of these tissues, interindividual variability in drug transporter protein expression is 
high. For example, expression of the uptake transporter MDR1 varies 3-6 fold in the 
intestine and up to 55-fold in the liver.13 Likewise, expression of uptake carriers such as 
OATP1B1 and OCT 1 can vary in hepatic tissues 20-80 fold.13 For many drug transporters 
in human liver tissues, the correlation between message and protein expression is weak.14 In 
lymphocytes, protein expression of MDR1 was inversely correlated with intracellular 
accumulation of MDR1 substrates including HIV protease inhibitors15, indicating protein 
expression may serve as a surrogate for drug transporter activity. Therefore, differences in 
mucosal exposure to antiretrovirals may be explained, at least in part, by variable drug 
transporter activity. To date, the knowledge of transporter expression in lower female genital 
and colorectal tissues is limited to evaluations in small sample sizes with techniques that are 
minimally quantitative.12,16-18
Maraviroc and tenofovir are two lead candidates for pre-exposure prophylaxis.2 For this 
focused investigation, we explored the expression of transporters known to affect the 
disposition of these two compounds, including three transporters from the ATP-binding 
cassette (ABC) family responsible for drug efflux from cells, and three transporters from the 
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solute carrier (SLC) family that facilitate drug uptake into cells. MPR2, MRP4, OAT1, and 
OAT3 have been implicated in tenofovir disposition19-22 while MDR1 and OATP1B1 affect 
maraviroc.23-25 We determined gene expression, protein localization, and estimated 
intersubject variability in ninety-eight mucosal tissues.
Materials and Methods
Tissue Procurement
Vaginal, cervical, and colorectal tissue samples, each from a unique donor, were procured 
from surgical waste specimens and from cadaver tissues from July 2009-January 2013. 
Surgical waste tissues were obtained through the UNC Tissue Procurement Facility (TPF) 
under two UNC IRB approved studies #09-0921 and #12-0368. Written informed consent 
was obtained from all participants. Demographic information including age, sex, race, 
surgical indication, smoking status, co-medications, and menopause status was collected via 
retrospective chart review. Prior to release from tissue procurement facility, all specimens 
were examined by a pathologist to ensure there were no abnormal pathologies. When tissue 
was collected from rectal carcinoma cases, all tissue used was >3 cm from tumor. Cadaver 
tissues were obtained from the National Disease Research Interchange (NDRI). Per NDRI 
protocol (http://ndriresource.org), all cadaveric donors signed a witnessed consent form 
prior to death. Tissues were procured within 3-10 hours post-mortem and shipped on ice 
overnight to our laboratory for processing. All tissue was collected under applicable 
regulations and guidelines regarding informed consent, protection of human subjects and 
donor confidentiality.
After harvest, all tissue was immediately placed on ice in Iscove's Modified Dulbecco's 
Medium until received into the laboratory. Ninety percent of samples were received within 6 
hours of harvest and no difference in mRNA expression was observed for those samples that 
were received after 6 hours (data not shown). For mRNA expression analysis, tissues were 
snap frozen in liquid nitrogen and stored at -80°C or preserved in RNALater ® (Qiagen, 
Hilden, Germany). When possible, a portion of the specimen was also fixed in formalin to 
be used for immunohistochemical protein expression analysis.
mRNA expression
Total RNA was extracted from 30 mg snap frozen or RNALater preserved tissues using the 
RNeasy Fibrous Tissue Kit (Qiagen). Tissues were homogenized in lysis buffer using 
Precellys Mixed Beads Homogenization Kit (Bectin Technologies, Villeurbanne, France) 
and underwent a 10 minute digestion in Proteinase K prior to RNA isolation and 
purification. RNA was quantified and tested for purity using a NanoDrop® UV 
Spectrometer (Thermo-Fisher Waltham, MA). RNA integrity was tested on a subset of 
samples using the Agilent Bioanalzyer 2100 (Agilent Technologies, Santa Clara,CA). First 
strand cDNA synthesis was performed from total RNA using Superscript® Vilo™ cDNA 
Synthesis kit (Life Technologies,Grand Island, NY) mRNA expression was quantified using 
quantitative PCR (qPCR) with TaqMan® Gene Expression Assays (ABCB1; 
Hs00184500_m1, ABCC2; Hs00166123_m1, ABCC4; Hs00988717_m1, SLC22A6; 
Hs00537914_m1, SLC22A8; Hs00188599, SLCO1B1; Hs00272374) on an ABI 7300 Real-
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Time PCR System (Life Technologies). Liver and kidney from healthy donors (First 
Choice®, Life Technologies, Grand Island, NY) were used as comparator organs. 
Expression was normalized to the expression of the endogenous control gene beta-actin 
(ACTB) (Hs99999903_m1) using the 2-ΔCt method.26 Earlier investigations demonstrated 
that among five candidate endogenous control genes selected, the ACTB gene, while still 
being expressed consistently >Ct 35, had the least variability in expression between female 
genital and colorectal tissues (see Supplementary Table 1).
To further investigate the role of physiologic factors in transporter expression, the gene 
expression of the efflux transporters in vaginal and cervical tissue was compared between 
premenopausal and postmenopausal women.
Protein expression
Tissues no greater than 5 mm thickness were formalin-fixed,embedded in paraffin molds, 
cut into 5 μm sections, and mounted on glass slides. The slides were deparaffinized in 
xylene and hydrated in a graded ethanol series. Slides were then stained using standard 
immunohistochemical techniques with primary antibodies for MDR1, clone JSB-1 
(catalogue # MAB4120, Millipore, Billerica, MA; 1:400 dilution), MRP2 clone M2III-5 
(catalogue #MC267, Kamiya, Seattle, WA; 1:50 dilution), MRP4 clone 1B2 (catalogue 
#H00010257-M03 Novus Biologicals, Littleton, CO; 1:1500 dilution), and OAT1 (catalogue 
#AB118346, Abcam, Cambridge, MA; 1:600 dilution) followed by staining with the 
secondary antibody (Leica Biosystems, ready-to-use Bond secondary antibody kit, 
approximately 10 minutes). For detection, DAB (3,3’-diaminobenzidine) was used as a 
substrate-chromogen (approximately 8 minutes). As reliable antibodies were not found for 
OAT3 or OATP1B1, immunohistochemical evaluations were not performed for these 
transporters. All stains were performed using the Leica Bond automated tissue stainer (Leica 
Biosystems Wetzlar, Germany). For positive and negative controls, normal human liver 
tissue was used for MDR1, normal human kidney tissue for MRP2 and OAT1, and normal 
human prostate for MRP4. Negative stains were performed using the secondary antibody 
only. To determine assay consistency, we initially stained 2 sections at least 30 μm apart 
from each of 9 cervical, 8 colorectal, and 10 vaginal donors. Since no intraindividual 
variability was noted the remainder of the samples was stained in singlet. Tissues stained 
with the secondary antibody alone were used as negative controls. Samples were evaluated 
for localization staining intensity as well as localization of expression.
Statistical Analysis
Association between continuous variables was evaluated with Spearman rank correlation. 
mRNA expression was compared between tissues types with an exact Kruskal-Wallis test, 
and when statistically significant (p<0.05), pairwise multiple comparisons were performed 
with Dunn's method. Tissue effect upon gene expression was further evaluated with a 
general linear model (GLM) adjusted for age (years), smoking status (yes/no), inducer co-
medication (yes/no), and hormone therapy (yes/no). Additional sensitivity analyses adjusted 
for race (Caucasian/African American), when known, in addition to the above covariates. 
mRNA expression was natural-log transformed to satisfy the GLM normality assumption. 
Pairwise tissue comparisons are presented as covariate-adjusted geometric mean ratios, and 
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were evaluated with the Tukey-Kramer multiple comparison method. Exact Wilcoxon rank-
sum tests were used to explore the effect of menopause upon gene expression within vaginal 
and cervical tissue.
All analyses were conducted two-sided at a 0.05 significance level. Statistical analyses were 
performed with SAS 9.2 (SAS Institute Inc. Cary, NC) and SigmaPlot 11.0 (Systat Software 
Inc. San Jose, CA).
Results
A total of 98 tissues, each from a unique donor, were procured and analyzed in this study. 
Demographic information for tissue donors is summarized in Table 1. Expression of each 
transporter gene is reported as the ratio to ACTB expression as outlined in the methods.
ABC Efflux Transporters
mRNA expression was measured in 40 vaginal, 30 cervical, and 21 colorectal tissue 
specimens. ABCB1, ABCC2, and ABCC4 were consistently expressed in all tissues analyzed. 
Figure 1 summarizes the expression results. mRNA expression of transporters were 
correlated (ABCB1 vs. ABCC2 r=0.73 p<0.001; ABCB1 vs. ABCC4 r=0.74 0. p<0.001; 
ABCC2 vs. ABCC4 r=0.66 p<0.001). The variability in raw Ct values for reference gene 
ACTB was 4.3, 9.4, and 4.8% for vaginal, cervical, and colorectal tissues respectively and 
overall variability was 6.5%. Preliminary analysis in 18 samples (5 vaginal, 6 cervical, 5 
rectal) showed that RNA integrity (determined by the Agilent Bioanalyzer) was not 
significantly correlated with mRNA normalized expression (r=0.22, p=0.3) indicating that 
our results were not influenced by RNA degradation.
For protein expression, sections from 30 vaginal, 27 cervical, and 11 colorectal specimens 
from surgical donors were evaluable for immunohistochemical interpretation. 
Representative images are displayed in Figure 2. Images of positive and negative control 
stains are showed in Supplemental Figure 1. Images at a lower magnification are included in 
Supplemental Figure 2.
ABCB1/MDR1—Median (Interquartile range (IQR)) expression ratios (to ACTB) for 
ABCB1 were 0.0402 (0.0178-0.0582), 0.0236 (0.0101-0.0524), and 0.0073 (0.0053-0.0208) 
for vaginal, cervical, and colorectal tissue, respectively. One colorectal sample did not have 
sufficient sample volume to include in the analysis. ABCB1 expression was 3-16% of 
comparator liver tissue and 1-5% of comparator kidney tissue. ABCB1 expression was 
different between the three tissue types (p <0.001), and was significantly higher in vaginal 
compared to colorectal tissues (p <0.05).
In a multivariable analysis, differences in ABCB1 expression between the tissue types 
remained significant after adjusting for age, smoking status, and co-medications (tissue 
effect, p<0.001). In the adjusted analysis, vaginal ABCB1 expression was 3.9 fold greater 
than colorectal ABCB1 expression (p<0.001). Results further adjusted for race were also 
significant (p<0.001). When tissues from cadaver donors were excluded, similar results were 
observed.
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Epithelial staining for MDR1 was observed in all vaginal, cervical, and colorectal tissues 
(Figure 2). Although there were no quantifiable differences in epithelial staining between 
tissue types, the squamous mucosa of the vaginal tissue and ectocervix showed qualitatively 
more intense and diffuse staining than in both the glandular mucosa of the endocervix and 
colorectal tissue. In these latter tissues, expression was largely limited to the luminal surface 
of the epithelium. Many submucosal lymphocytes in all tissue types also stained 
positive.Lymphoid follicles, when present, showed strong positive staining for MDR1.
ABCC2/MRP2—Median (IQR) expression values for ABCC2 were 0.0014 
(0.0008-0.0025), 0.0009 (0.0004-0.0016), and 0.0003 (0.0001-0.0011) for vaginal, cervical, 
and colorectal tissues, respectively. This expression was 1-3% of the comparator liver tissue 
and <1% of the comparator kidney tissue. ABCC2 expression was different between the 
three tissue types (p <0.001) and was significantly higher in vaginal compared to colorectal 
tissues (p<0.05). In a multivariable analysis, differences in ABCC2 expression between the 
tissue types remained significant after adjusting for age, smoking status and co-medications 
(tissue effect, p<0.01). In the adjusted analyses, vaginal ABCC2 expression was 2.9-fold 
greater than colorectal ABCC2 expression (p<0.001). The tissue effect remained significant 
when further adjusted for race (p<0.01) and when cadaver tissues were excluded.
Diffuse staining was observed in the epithelia of all tissues types without any notable 
difference between tissue types. Similar to MDR1, positive staining was observed in 
submucosal lymphocytes and in lymphoid follicles of vaginal, cervical and colorectal 
tissues.
ABCC4/MRP4—Median (IQR) expression values for ABCC4 were 0.0193 
(0.0131-0.0291), 0.0097 (0.0061-0.0226), and 0.0237 (0.0122-0.0368) for vaginal, cervical, 
and colorectal tissues, respectively. This expression is 120-310% of the comparator liver and 
6-14% of the comparator kidney. ABCC4 expression was different between the three tissue 
types (p<0.05) with expression significantly higher in colorectal versus cervical tissues 
(p<0.05). In a multivariable sensitivity analysis, the differences in ABCC4 expression 
remained significant after adjusting for age, smoking status, and co-medications (tissue 
effect, p<0.05). In the adjusted analysis, colorectal ABCC4 expression was 2.0-fold greater 
than cervical ABCC4 expression (p<0.05). The tissue effect did not reach significance when 
further adjusted for race (p=0.18). When tissues from cadaver donors were excluded, similar 
results were observed.
Epithelial staining was observed in all tissue types, with the most intense staining identified 
in endocervical glandular mucosa faint diffuse staining in vaginal squamous epithelium ,and 
very faint focal staining in colorectal columnar epithelium. While a subset of submucosal 
lymphocytes and monocytes were also positive in all three tissue types, the highest 
expression was observed in colorectal samples where staining was primarily localized to the 
luminal surface of the epithelium. Primary follicles in the colorectal tissue showed no 
definitive staining, although germinal centers of secondary follicles, present for evaluation 
in two samples, were moderately positive for MRP4 expression.
Nicol et al. Page 6
J Clin Pharmacol. Author manuscript; available in PMC 2015 May 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
SLC Uptake Transporters
The SLC transporters were expressed in less than 25% of all mucosal tissues. These results 
are summarized in Table 2. Detecting one SLC gene did not increase the likelihood of 
detecting another SLC gene from the same sample. For example, there were three cervical 
samples with quantifiable SLC22A6 mRNA expression and three cervical samples with 
quantifiable SLC22A8 mRNA expression: only one of these samples had quantifiable levels 
of both genes. No tissue samples had all three SLC genes quantifiable.
SLC22A6/OAT1—SLC22A6 was quantifiable in only 5% of samples and of those samples, 
expression was <0.1% of the kidney comparator tissue.
Similarly, no protein expression was observed in vaginal or cervical (Figure 2) samples by 
immunmohistochemistry. However, all colorectal samples had scattered cells within the 
epithelium that showed intense staining. Morphologically, these cells most likely represent 
true colorectal epithelial cells rather than intraepithelial lymphocytes, monocytes, or plasma 
cells. These cells comprise <1 per 500 epithelial cells at a frequency of <0.5 per 600x high 
power field.
SLC22A8/OAT3 and SLCO1B1/OATP1B1—SLC22A8 was quantifiable in 8% of all 
samples and expression was <0.01% of the kidney comparator. SLCO1B1 was quantifiable 
in 14% of all samples and was <0.1% of expression in the liver comparator. As described in 
methods, immunohistochemical evaluations were not performed for these 2 transporters.
Role of menopause status in efflux transporter mRNA expression
In vaginal tissue, mRNA expression was compared between 22 postmenopausal and 13 
premenopausal women. Median ABCB1 expression was decreased by 17% in 
postmenopausal compared to premenopausal (p<0.05). ABCB1 expression within vaginal 
tissue also negatively correlated with age (r=-0.426, p<0.01). Median vaginal tissue 
expression of ABCC2 and ABCC4 were reduced in postmenopausal women by 11% and 
28% respectively, but these did not reach statistical significance (p=0.26 and p=0.12). 
Within cervical tissue, mRNA expression was compared between 16 postmenopausal and 11 
premenopausal women. There was no observed difference in cervical expression of ABCB1, 
ABCC2 or ABCC4. Because there was only one premenopausal donor in the colorectal 
group, no analysis was done with this tissue type.
Discussion
To our knowledge, these data represent the most robust evaluation of drug transporter 
quantification and localization in female genital and colorectal tissues to date. Based on 
affinity for maraviroc and tenofovir, two candidates for HIV prevention that show different 
distribution patterns in female genital tract and colorectal tissue, we chose three efflux 
transporters from the ABC family (ABCB1/MDR1/P-glycoprotein, ABCC2/MRP2, and 
ABCC4/MRP4) and three uptake transporters from the SLC family (SLC22A6/OAT1, 
SLC22A8/OAT3, and SLCO1B1/OATP1B1). We found that efflux transporters MDR1, 
MRP2, and MRP4 are consistently expressed in both female genital and colorectal tissues, 
Nicol et al. Page 7
J Clin Pharmacol. Author manuscript; available in PMC 2015 May 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
but to different extents and with unique cellular localizations. At the mRNA level, vaginal 
tissue has the highest expression of ABCB1 and ABCC2 while ABCC4 is most highly 
expressed in colorectal tissues. Uptake transporters SLC22A6, SLC22A8, and SLCO1B1 are 
expressed in a minority of samples at the mRNA level, and colorectal epithelial cells express 
very low levels of OAT1.
The differential tissue expression profiles for each transporter observed in our study may 
assist with understanding how drugs are distributed to, and accumulate within, mucosal 
tissues (Figure 3). For drugs being considered for use in PrEP (such as a fixed dose 
combination tablet of two nucleoside/tide reverse transcriptase inhibitors emtricitabine and 
tenofovir disoproxil fumarate (FTC/TDF), and the CCR5 antagonist maraviroc) mucosal 
penetration is of great interest. A healthy volunteer study measuring vaginal, cervical, and 
colorectal penetration following a single oral dose of FTC/TDF found tenofovir and 
tenofovir diphosphate exposures 100-fold higher in colorectal tissue than in female genital 
tract tissue.8 Both in vitro and clinical data have demonstrated that tenofovir is a substrate 
for the efflux transporter MRP4.19 The immunohistochemical data for MRP4 displayed a 
distinct staining profile in the colorectal tissues with intense staining observed in the 
submucosal lymphocytes and faint staining observed in the epithelial layers. Less expression 
of efflux transporter specifically in the epithelial layer may imply less overall efflux from 
the tissue (Figure 3A). Tenofovir has also been implicated as an MRP2 substrate although its 
role in cellular disposition is less clear.20 Both mRNA and protein expression suggest MRP2 
expression is greater in vaginal compared to colorectal epithelium. Similar to MRP4, less 
expression of MRP2 in colorectal epithelium may contribute to less efflux of tenofovir from 
the tissue (Figure 3A). Tenofovir has also been shown in vitro to be a substrate for the 
uptake transporter OAT1 and to a lesser extent OAT3.21,22 OAT1 expressing cells were not 
found in any of the vaginal or cervical tissues evaluated for protein. However, each of the 
colorectal tissues examined had isolated cells in the epithelium that clearly expressed the 
OAT1 uptake transporter. The overall abundance of these OAT1 expressing cells was low, 
although higher expression in colorectal versus female genital tissues may contribute to the 
greater accumulation of tenofovir in colorectal tissues8 (Figure 3A). Additionally, tenofovir 
bioavailability is 25%, therefore colorectal luminal concentrations are likely high and would 
facilitate tissue uptake despite low transporter expression.27
Currently in early phase studies for PrEP, maraviroc is a known substrate of MDR1.23-24 
Higher expression of the efflux transporter MDR1 in vaginal versus colorectal tissues is 
consistent with clinical findings that maraviroc accumulation is greater in colorectal tissues6 
than in the female genital tract (Figure 3B).7 Maraviroc has also been implicated as a 
substrate for OATP1B125, however this transporter was not found to be expressed in either 
female genital or colorectal tissues.
Although mRNA expression does not always correlate with protein expression14,28, the use 
of immunohistochemical evaluations supported our mRNA expression results in these 
tissues. MRP4 and OAT1 antibodies for immunohistochemistry had reliable performance 
and low inter-batch variation. MDR1 and MRP2 antibodies were more challenging to 
validate and maintain. The poor quality of available antibodies limited our ability to perform 
quantitative analysis of protein expression. However, consistent staining of MDR1, MRP2, 
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and MRP4 in all tissues and sparse staining of OAT1 in colorectal tissue supported the 
mRNA measures of pan-detectable ABC transporters and sparsely detectable SLC 
transporters. MDR1 and MRP2 staining was mostly localized to the epithelium with some 
staining in submucosal monocytes and lymphocytes. Since the squamous epithelium of 
vaginal and ectocervical tissue has many more layers of epithelial cells than the single 
columnar layer of the colorectal tract, this may explain why the mRNA expression for these 
transporters was higher in vaginal than colorectal tissues. Conversely, MRP4 was only 
modestly detected in the epithelium in all tissues but was most remarkable in the 
submucosal lymphocytes and monocytes in the colorectum. Since the colorectum is highly 
colonized with these submucosal immune cells and lymphoid follicles29, this may explain 
the significantly higher ABCC4 mRNA expression in colorectal compared to cervical 
tissues.
While expression in the intestinal tract has been previously explored for certain transporters, 
the emphasis has been on their role in drug absorption with most studies have focusing on 
the small intestine.12,30-31 Our data in 98 individuals has been confirmed with recent 
published reports. Hilgendorf et al. reported that ABCB1/ABCC4 mRNA expression in colon 
was similar to expression in liver, kidney, and jejunum.31 Nishimura et al , found 
undetectable mRNA expression of SLC22A6 and SLC22A8, low mRNA expression of 
ABCC2, moderate expression of ABCB1, and high expression of ABCC4 in colonic 
tissues.12 De Rosa et al. found a similar trend for mRNA expression.18
In the female genital tract of 12 individuals, a recent study by Zhou et al. used conventional 
PCR to evaluate mRNA expression of 22 drug transporters and 19 metabolizing enzymes.17 
This study found that MRP4 mRNA was highly expressed, MDR1 modestly expressed, and 
MRP2 and OAT1 were undetectable. This investigation only documented the presence or 
absence of mRNA and did not provide information on interindividual variability, protein 
expression, or protein localization.
Many factors contribute to the regulation of transporter expression including genotypic 
polymorphisms, inflammation, and xenobiotics.32-35 A role for sex steroid regulation in drug 
transporter expression has been proposed based on significant differences in endometrial 
MDR1 expression across the menstrual cycle.36 These findings have been supported by in 
vitro data in various cell lines.37,38 Within vaginal tissue, we saw a 17% decrease in the 
expression of ABCB1 in post-menopausal women suggesting that estrogen may play a role 
in the in vivo regulation of this gene. Since post-menopausal women are also at risk for HIV 
acquisition39, future studies are needed to elucidate the effect of estrogen status on mucosal 
drug exposure in post-menopausal women. Expression between transporters was modestly 
correlated, suggesting at least some degree of co-regulation in gene expression. Despite 
these correlations, differences were observed between transporters in the rank order of tissue 
expression (i.e. vaginal>cervical>colorectal for ABCB1 and ABCC2; 
colorectal>vaginal>cervical for ABCC4) which is noteworthy.
There are limitations to this investigation. From this analysis, the functionality of these 
transporters could not be determined. Also, our study was not performed in “healthy 
volunteers” but rather surgical and cadaver donors. The surgical procedures performed were 
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primarily for structural reasons (vaginal/rectal prolapse, 60%) and there are no data on the 
effect these may have on transporter expression. Additionally, our results were similar when 
cadaver tissues were excluded. Finally, although there are over 400 membrane transporters 
annotated in the human genome10, because of the limited sample available from each donor, 
only six targeted membrane transporters were evaluated in this analysis Given the 
importance of mucosal tissue transporter localization for PrEP, we chose to use 
immunohistochemistry to evaluate protein expression. Now that localization of these 
transporters is better understood, quantifying protein concentrations using quantitative 
targeted proteomics may provide more information on the correlations between mRNA and 
protein concentrations in the future.40
In conclusion, in support of the development of PrEP agents, this investigation quantified 
the interindividual and intertissue variability of mRNA expression for six membrane drug 
transporters important to tenofovir and maraviroc disposition, and determined protein 
expression and localization in vaginal, cervical, and colorectal tissues. We found higher 
expression of the efflux transporter MDR1 and MRP2 and lower expression of OAT1 in the 
female genital tract compared to colorectal tissues. Although MRP4 expression was higher 
in colorectal tissues at the mRNA level, protein expression in colorectal epithelium was 
minimal. This may explain why the MDR1 substrate maraviroc, and MRP2/4 and OAT 1 
substrate tenofovir achieve higher concentrations in colorectal tissues compared to vaginal 
or cervical tissue. Identifying which transporters play key roles in controlling drug 
distribution into female genital and/or colorectal tissues will streamline the candidate 
selection process for compounds requiring high mucosal exposure. Data generated from 
investigations such as this one can also be applied beneficially to therapeutic areas such as 
sexually transmitted diseases, gynecological disorders, and gastrointestinal diseases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
mRNA expression of three ABC transporters in vaginal, cervical, and colorectal tissues. 
mRNA was detected by qRT-PCR and levels were normalized to ACTB Ct values using the 
2-ΔCt method. Box plots represent the 50th percentile (line), 25th and 75th percentile (box), 
10th and 90th percentile (error bars), and outliers (circles). Tissues were compared using an 
exact Kruskal Wallis test and pairwise comparisons were made using the Dunn's method * 
p<0.05
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Figure 2. 
Immunohistochemical staining of vaginal, cervical, and colorectal tissues. Black arrows 
identify expression efflux transporters expressed in the epithelial layers. Submucosal 
lymphocytes and/or monocytes are highlighted by the yellow arrows. The red arrow 
identifies a rare positive columnar epithelial cell. Images of OAT1 expression in vaginal and 
cervical tissue, and MDR1 in vaginal tissue were taken at an original objective 
magnification of 20x, and all others at an original magnification of 60x.
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Figure 3. 
Hypothesized influence of drug transporters on drug exposure in colorectal and vaginal 
tissues. The differential expression between colorectal and vaginal epithelial tissues for each 
transporter relevant to a specific substrate's drug distribution is summarized. A) Tenofovir is 
a substrate for MRP2, MRP4, and OAT1 B) Maraviroc is an MDR1 substrate. The black 
circles represent the respective drug molecules. The relative in vivo tissue exposures 
observed (colorectal:vaginal) following oral doses is summarized in the boxes to the left of 
the schematic.
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Table 1
Demographics of Tissue Donors.
Demographic Parameters Vagina Cervix Rectum
n=47 n=31 n=21
Age median (range) 58 (36-84) 54 (39-83) 56.5 (25-92)
Males n (%) 0 (0) 0 (0) 9 (4)
Females n (%) 47 (100) 31 (100) 11 (52)
Race n (%) Caucasian 39 (83) 19 (61) 18 (86)
African American 4 (9) 7 (23) 1 (5)
Asian 0 (0) 1 (3) 1 (5)
Native American 1 (2) 0 (0) 0 (0)
Mixed 0 (0) 1 (3) 0 (0)
Unknown 3 (6) 3 (10) 1 (5)
Surgical Donor n (%) 46 (98) 31 (100) 14 (67)
Primary Surgical Indication Vaginal or rectal prolapse/rectocele 38/4 3/0 1
Stress urinary incontinence 3
diverticulum 1
Pelvic or adnexal mass 12
endometrial cancer or uterine fibroids 10
history of breast cancer or BRCA positive 3
abnormal pathologies 3
rectal carcinoma 12
Cadaver Donor n (%) 1 (2) 0 7 (33)
Cause of death cerebrovascular accident/subarachnoid hemorrhage 1/0 1/1
cardiopulmonary arrest/myocardial infarction 2/1
amyotrophic lateral sclerosis 1
anoxic encephalopathy 1
Smoker n (%) 8 (17) 7 (23) 11 (52)
Co-medications n (%) inducers 21 (45) 19 (61) 8 (38)
hormones 14 (30) 4 (13) 0 (0)
Menopause n (%)
postmenopausal 25 16 5
Pre or peri-menopausal 14 12 1
Included in mRNA analysis n (%)* 40 (85) 30 (97) 21 (100)
Included in IHC analysis n (%)* 30 (64) 27 (87) 11 (52)
Demographic information regarding donors of tissue specimens is reported. One rectal surgical sample did not have any demographic information 
available. Inducers included phenytoin, simvastatin, atorvastatin, nifedipine, omeprazole, carbamazepine, lamotrigine and topiramate. Hormones 
included estrogen replacement therapy administered orally or vaginally as well as oral or long-active contraceptive therapy.
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*
The majority of tissues were evaluated for both protein and RNA expression. However, some samples (vagina n=6; cervix n=1) did not yield 
enough RNA to perform qRT-PCR, and some samples (vagina n=16, cervix n=4, colorectum n=10) did not have tissue available for 
immunohistochemistry.
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Table 2
The proportion of samples for each transporter with quantifiable mRNA expression. The range of expression 
values (normalized to ACTB expression using 2−ΔCt) when detected is included in parenthesis.
Tissue OAT1 SLC22A6 OAT3 SLC22A8 OATP1B1 SLC01B1
% Quantifiable (range) % Quantifiable (range) % Quantifiable (range)
Vagina (n=40) 0 (0) 5 (3.4 × 10−5 – 4.5 × 10−5) 10 (6.0 × 10−6 - 1.3 × 10−4)
Cervix (n=30) 10 (2.2 × 10−5 – 1.6 × 10−4) 10 (1.8 × 10−6 - 7.4 × 10−5) 27 (9.4 × 10−6 – 1.6 × 10−4)
Rectum (n=21) 9.5 (8.5 × 10−6 - 6.4 × 10−4) 9.5 (2.3 × 10−6 – 6.0 × 10−6) 9.5 (1.5 × 10−6 – 2.8 × 10−6)
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